SecBot SecBot
8-K ·Filed May 7, 2026

STOK

Stoke Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0001193125-26-212020
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The EPS beat is marginal and overshadowed by the non-recurring revenue drop. Focus on Phase 3 enrollment completion in June 2026 and mid-2027 data readout. The strong cash runway reduces near-term dilution risk but ATM sales remain an overhang. Monitor any regulatory milestones regarding zorevunersen.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$32.89
T+0 close · May 7, 2026 · via day close
Latest settled
−3.71%
T+60 · $31.67
Vs SPY
−8.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $32.89entry
  2. T+1 · 6mo ago −0.76%α −0.99% · $32.64
  3. T+5 · 6mo ago −4.65%α −6.12% · $31.36
  4. T+20 · 5mo ago −8.76%α −8.78% · $30.01
  5. T+60 · 3mo ago −3.71%α −8.55% · $31.67

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Stoke Therapeutics reported Q1 2026 net loss of $50.0M ($0.79 per share) vs net income of $112.9M in Q1 2025, which included a $150.8M Biogen license fee. Revenue fell to $6.2M from $158.6M. The company highlighted continued Phase 3 EMPEROR enrollment on track for June 2026 completion and a cash position of $411M funding operations into 2028.

Key Financial Metrics

EPS
−$0.79
est −$0.80 · +1.3%
Revenue
$6.2M
-96.1% YoY
Rating
in line

Key Facts

  • Net loss $50.0M ($0.79 per share) vs net income $112.9M ($1.90 diluted) in Q1 2025
  • Revenue $6.2M down 96% YoY due to $150.8M prior-year Biogen IP license
  • Cash, cash equivalents and marketable securities $411.0M as of March 31, 2026
  • Phase 3 EMPEROR enrollment of ~150 patients on track to complete June 2026; data readout mid-2027
  • Raised $80.7M via ATM sales of 2.6M shares in Q1 2026

Financial Impact

Net loss per share of $0.79 slightly beat consensus of $0.80, but revenue miss is not comparable due to license timing. Cash runway extended into 2028.

revenuenet_incomecash

Risk Factors

  • Phase 3 EMPEROR data may fail to replicate Phase 1/2a efficacy
  • Dilution risk from continued ATM sales ($80.7M raised in Q1 2026)
  • Regulatory delays or additional data requests from FDA

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-212020
Document: stok-20260507.htm0001193125-26-212020
Document: 0001193125-26-212020-index-headers.html0001193125-26-212020
Document: 0001193125-26-212020-index.html0001193125-26-212020
Document: 0001193125-26-212020.txt0001193125-26-212020
8-K Data (Synthetic)0001193125-26-212020

Track record

18 reports on STOK

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +17.49% at T+60 after the Aug 3, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $27.02 Now $26.63 −1.44% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $26.12 Now $26.63 +1.95% settles Feb 12
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $26.07 Now $26.63 +2.15% settles Feb 3
  6. Oct 29, 202618d ago 8-K Neutral 5/10 Entry $26.29 Now $26.63 +1.29% settles Jan 28
  7. Oct 21, 202626d ago 144 Bearish 6/10 Entry $25.70 Now $26.63 −3.62% settles Jan 20
  8. Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $26.01 Now $26.63 +2.38% settles Dec 28
  9. Sep 25, 20267w ago 8-K Neutral 2/10 Entry $25.50 Now $26.63 +4.43% settles Dec 22
  10. Aug 18, 202612w ago Insider Cluster Neutral 3/10 Entry $33.03 to $26.20 Now $26.63 −19.38% ▼ −20.68% −19.13% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (10h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026